Glenmark Expands Portfolio With New Ophthalmic Treatment In The U.S.

Glenmark Pharmaceuticals Inc., USA, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). This product is bioequivalent and therapeutically equivalent to Travatan Z® Ophthalmic Solution USP, 0.004%, developed by Sandoz, Inc.

Based on IQVIA sales data, the Travatan Z® market recorded annual sales of approximately $66.2 million for the 12 months ending September 2024. Glenmark’s introduction of this solution aims to strengthen its presence in the U.S. market for ophthalmic treatments.

Jim Brown, Senior Vice President of Sales & Marketing, said, “We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004%, growing our portfolio of prescription ophthalmic products. This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers.”

Glenmark’s present portfolio in the U.S. includes 200 products authorised for distribution and 51 ANDAs pending FDA approval. The company also actively runs external development partnerships to expand and enhance its pipeline and product offerings.